During cancer progression, the upregulation of PD-1 ligands (PD-L1 and PD-L2) on tumor or immune cells in the tumor microenvironment activates this immunosuppressive pathway, enabling tumors to evade anti-tumor immune surveillance (30). Here, PDCD1LG2 is linked to neoplasm.